Intermittent Fasting for Blood Sugar
Intermittent fasting is a group of eating patterns that set when food is eaten: a daily eating window, two or three very-low-energy days a week, alternating days, or the dawn-to-sunset fast of Ramadan. In randomized controlled trials in adults with type 2 diabetes these patterns lowered body weight and, in most but not all pooled analyses, hemoglobin A1C (HbA1c), the blood test that reflects average blood sugar over about three months. Set against ordinary daily calorie restriction, fasting came out about equal for HbA1c. The main hazard in the research is low blood sugar in people who take insulin or sulfonylurea drugs.
Evidence base: in type 2 diabetes, randomized controlled trials of 6 weeks to 12 months and meta-analyses that do not all agree; for Ramadan fasting, a systematic review, narrative reviews and consensus statements; for type 1 diabetes, no trial among this page's sources.
Table of Contents
- What Intermittent Fasting Is
- How Fasting Affects Blood Sugar
- What the Trials Found in Type 2 Diabetes
- Fasting Compared With Daily Calorie Restriction
- Eating Windows Early in the Day
- Ramadan Fasting and Diabetes
- What Guidelines State
- Safety Findings
- Limits of the Evidence
- Key Research Papers
- Connections
- Featured Videos
What Intermittent Fasting Is
Fasting here means going without food, or eating very little, for a set period. The trials tested several patterns. Their results are kept apart on this page, because a result for one pattern does not transfer to another.
- Time-restricted eating. All of the day's food is eaten inside a window, "typically 4 to 8 hours", with a fast for the remaining hours of the day (PMID 39193706).
- Early time-restricted eating. The window sits early in the day. In the first trial of it, dinner was eaten before 3 pm (PMID 29754952).
- 5:2 intermittent energy restriction. On two non-consecutive days a week the person eats 500–600 kilocalories; on the other five days, the usual diet (PMID 30646030).
- Three fasting days a week, non-consecutive, in two trials (PMID 36508320, PMID 37024596).
- Alternate-day fasting. Fasting days alternate with eating days. No single trial of this pattern in people with diabetes is among this page's sources; it appears only inside a pooled analysis of adults with varied health conditions (PMID 40533200).
- Ramadan fasting. A religious fast: no food and no drink between dawn and sunset for 30 consecutive days (PMID 33763029).
Clock times in the diagram are examples from single trials; windows differed from trial to trial.
How Fasting Affects Blood Sugar
After some hours without food, insulin falls and the body turns from the sugar of the last meal to stored fuel. A 2020 review examines what its authors call the proposed "metabolic switch" as a mechanism behind the effects of fasting (PMID 32372521).
Less food is eaten. In a 6-month randomized clinical trial, adults with type 2 diabetes who ate only inside an 8-hour window, without counting calories, reduced their energy intake by a mean of 313 kilocalories a day. The group told to count calories reduced theirs by 197, the control group by 16 (PMID 37889487).
Weight falls. Body weight fell in the fasting groups of the trials below, and HbA1c usually fell with it, so most trials cannot separate the effect of fasting from the effect of weight loss.
An effect apart from weight loss, in one small trial. A supervised feeding trial was designed to remove weight loss from the picture. Men with prediabetes were randomized to eat either in a 6-hour period with dinner before 3 pm or over a 12-hour period for 5 weeks, then crossed over. They were given enough food to keep their weight steady. The early 6-hour schedule improved insulin sensitivity, the responsiveness of the insulin-making beta cells, blood pressure, oxidative stress and appetite. The authors call it a proof-of-concept study; its abstract reports no blood sugar figures (PMID 29754952).
What the Trials Found in Type 2 Diabetes
Time-Restricted Eating
A 6-month randomized clinical trial enrolled 75 adults with obesity and type 2 diabetes (mean HbA1c 8.1%). One group ate only from noon to 8 pm with no calorie counting, one cut energy intake by 25% every day, and one was a control group. Relative to controls, body weight fell 3.56% in the time-restricted group (P = .004) and HbA1c fell 0.91%. That group kept to its window on a mean of 6.1 days per week. Time in the normal glucose range, a score of diabetes medication use, blood pressure and blood lipids did not differ among the groups. No serious adverse events were reported (PMID 37889487).
A randomized crossover trial in 39 overweight adults with early type 2 diabetes (baseline HbA1c 6.6%) compared 6 weeks of 20 hours of fasting and 4 hours of eating each day with standard lifestyle. HbA1c fell (−0.32 ± 0.48%; P < .001), body weight fell 3.86%, and a measure of how well the beta cells respond to glucose rose 14%. Fasting glucose did not differ between the two periods (PMID 39193706).
The 5:2 Pattern
The longest 5:2 trial, 12 months, compared it with daily calorie restriction and is set out in the next section.
A 16-week randomized, open-label trial at 9 centers in China assigned 405 adults with overweight or obesity and early type 2 diabetes (mean HbA1c 7.9%) to metformin, to empagliflozin, or to a 5:2 plan built on meal replacements; 332 completed treatment. HbA1c fell 1.9% in the 5:2 group, 1.6% with metformin and 1.5% with empagliflozin, and the differences were statistically significant. Weight fell 9.7 kg, 5.5 kg and 5.8 kg. Follow-up after treatment was 8 weeks; the authors describe the result as short-term. In an open-label trial everyone knows which treatment they have (PMID 38904963).
Fasting Days in People Taking Insulin
A 12-week randomized controlled trial assigned 46 people with insulin-treated type 2 diabetes to 3 non-consecutive fasting days per week or to a control group. Both groups received dietary counseling and continuous glucose monitoring. HbA1c changed by −7.3 ± 12.0 mmol/mol in the fasting group and 0.1 ± 6.1 mmol/mol in the control group (P = 0.012); the trial reports HbA1c in mmol/mol, the international unit, not in percent. A combined target (weight reduction ≥2%, insulin dose reduction ≥10% and HbA1c reduction ≥3 mmol/mol) was reached by 8 people in the fasting group and none in the control group. No severe hypoglycemia occurred (PMID 36508320).
Remission in One Trial
One randomized controlled trial tested whether an intermittent calorie-restricted diet could bring remission, defined as HbA1c below 6.5% for at least 3 months after discontinuing all antidiabetic medications. Participants were aged 38 to 72, had had type 2 diabetes for 1 to 11 years, and were using antidiabetic agents, insulin or both. After a 3-month intervention and 3 months of follow-up, 47.2% (17 of 36) of the diet group and 2.8% (1 of 36) of the control group met the definition. Mean body weight fell 5.93 kg against 0.27 kg. At the 12-month follow-up, 44.4% (16 of 36) were still in remission. This is a single trial with 36 people per group (PMID 36515429).
What the Pooled Analyses Found
A meta-analysis pools the results of many trials. These do not agree with each other.
- A 2024 meta-analysis of 14 randomized trials in 1101 adults with prediabetes or type 2 diabetes: against a control diet, fasting lowered body weight by 4.56 kg, HbA1c by 0.81% (95% confidence interval −1.24 to −0.38) and fasting glucose by 0.36 mmol/L. It did not significantly lower fat mass, insulin or blood pressure. Against calorie restriction, weight was 1.14 kg lower with fasting, with no significant effect on HbA1c (PMID 38956175).
- A 2025 meta-analysis of sixteen randomized controlled trials with 5369 patients with type 2 diabetes: fasting improved HbA1c, fasting plasma glucose and body weight compared with control, with no significant difference in blood sugar after meals (PMID 40008664).
- A null result. A 2023 meta-analysis of eleven studies (13 arms) in type 2 diabetes found no statistically significant difference in HbA1c between fasting and control groups (standardized mean difference −0.08; 95% confidence interval −0.20 to 0.04; p = 0.19), and none in fasting blood glucose across seven studies (p = 0.69). Its authors concluded that intermittent fasting and a usual diet pattern "have no difference in terms of glycaemic control" (PMID 37313231).
- A null result for HbA1c. A 2025 network meta-analysis of 99 randomized clinical trials in 6582 adults of varying health conditions found no differences in HbA1c between intermittent fasting, continuous energy restriction and unrestricted diets. For weight, alternate-day fasting was the only pattern that beat continuous restriction (−1.29 kg, moderate certainty), and in trials of 24 weeks or longer the weight benefits appeared only against unrestricted diets (PMID 40533200).
Fasting Compared With Daily Calorie Restriction
Fasting days and eating windows cut food intake, so the fair test is against a diet that cuts intake every day. Three trials made that comparison.
| Study | People | Fasting pattern | Compared with | Length | Result |
|---|---|---|---|---|---|
| Randomized clinical trial, 2023 (PMID 37889487) | 75 adults with obesity and type 2 diabetes | Eating from noon to 8 pm only, no calorie counting | 25% less energy every day | 6 months | HbA1c: no difference between the two diets (−0.91% and −0.94% relative to controls). Weight relative to controls: −3.56%, significant, and −1.78%, not significant (P = .06). |
| Randomized noninferiority trial, 2018 (PMID 30646030) | 137 adults with type 2 diabetes; 97 completed | 5:2, with 500–600 kilocalories on 2 non-consecutive days a week | 1200–1500 kilocalories every day | 12 months | HbA1c: −0.3% with 5:2 and −0.5% with daily restriction (P = .65), meeting the trial's preset test of equivalence. Weight: −6.8 kg and −5.0 kg (P = .25); the preset test of equivalence for weight was not met. Fasting glucose and the medication score did not differ. |
| Randomized controlled trial, 2023 (PMID 37024596) | 209 adults at increased risk of type 2 diabetes | Three fasting days a week, with food only from 8 am to noon on those days | 70% of energy needs every day | 6 months, then 12 months of follow-up | Blood sugar response to a test meal improved more with fasting at month 6 (P = 0.03). The difference was lost at month 18. |
Read with the pooled analyses above, these studies found fasting equal to daily calorie restriction for HbA1c, not better. Equivalence is a finding in its own right: in these trials fasting was another route to the same blood sugar result.
Two reviews reach the same reading. A 2020 review concluded that the limited evidence suggests intermittent fasting has "a similar effectiveness compared with calorie-restriction diets for weight loss and improvement in glycaemic variables" (PMID 32372521). A 2026 Personal View article states that it "is as effective as calorie restriction for improving glycaemic control" (PMID 42361830).
Eating Windows Early in the Day
Some trials placed the eating window in the morning and early afternoon. The supervised feeding trial in men with prediabetes, described above, is one; the trial of three fasting days a week with food from 8 am to noon is another.
A 12-week randomized controlled trial compared an early window with a late one directly. Its 59 participants had metabolic dysfunction-associated steatotic liver disease (fatty liver disease), and all three groups followed a reduced-calorie Mediterranean-type diet: one with no time limit, one eating from 8 am to 6 pm, one from noon to 10 pm. All groups lost weight. HbA1c and measures of insulin resistance improved in the early group at 12 weeks (PMID 40017349).
None of the type 2 diabetes trials on this page compared an early window with a late one; the 6-month trial in type 2 diabetes used noon to 8 pm. The evidence for early windows comes from people with prediabetes, at risk of diabetes, or with fatty liver disease.
Ramadan Fasting and Diabetes
The Ramadan fast differs from the diets above: no water is taken during the fasting hours, the fast repeats daily for a month, and its purpose is religious. A 2025 consensus statement gives its length as 11–16 hours a day on average, depending on season and place (PMID 40512040).
A 2021 systematic review collected 68 studies (35 randomized controlled trials and 33 observational studies) of people with type 2 diabetes who fasted during Ramadan, with low blood sugar events as the main outcome. It notes that earlier reports conflict on how often such events occur. Its clearest finding concerns medication: drugs other than sulfonylureas were superior to sulfonylureas in lowering the incidence of low blood sugar events. Sex, country, season, body measurements, dietary behaviors, length of the fast, time since diagnosis and education before the fast were each associated with the risk (PMID 33763029).
A 2017 review states that fasting during Ramadan can cause wide swings in blood sugar and raises the risk of acute complications: low blood sugar, high blood sugar, diabetic ketoacidosis, dehydration and thrombosis (blood clots). It adds that education, sorting people by risk and changing antidiabetic medications can reduce the risk (PMID 28530893).
On diabetic ketoacidosis the reviews differ. A 2019 narrative review traced the warning to early expert opinion "proposed with no evidence" and reported that recent retrospective, prospective and database studies "could not document any increase" in diabetic ketoacidosis during Ramadan. It excepts people who carry the usual risk factors for metabolic decompensation (PMID 30836132).
What Guidelines State
General diabetes guidelines. A 2026 Personal View article by three fasting researchers reports that, despite more than 225 clinical trials, intermittent fasting "has not yet been recommended" in the American Diabetes Association Standards of Care or the International Diabetes Federation Global Clinical Practice Recommendations. The authors argue that the evidence now warrants listing it as one of several lifestyle options for type 2 diabetes. That is the authors' argument, not a guideline (PMID 42361830).
Ramadan guidance. According to a 2023 summary, the guideline of the International Diabetes Federation and the Diabetes and Ramadan International Alliance calls for a visit at least 6–8 weeks before Ramadan and sorts people with diabetes into three risk groups (very high, moderate and low). Education covers risks, glucose monitoring, nutrition, exercise and medication adjustment, and the summary reports that studies have shown such counseling reduces the incidence of low blood sugar. People in the highest risk classes, including people with type 1 diabetes and pregnant women with diabetes, "need close medical supervision" if they fast (PMID 36932771).
A 2025 consensus statement recommends giving priority to drug therapies with a low risk of low blood sugar and supports continuous glucose monitoring during the fast. It states that the effect of Ramadan fasting on atherosclerotic cardiovascular disease (disease of narrowed arteries) is uncertain, that the literature suggests an increased risk, and that until better evidence is reported it advises people at high risk of that disease against fasting in Ramadan (PMID 40512040).
Safety Findings
Low Blood Sugar With Insulin or Sulfonylureas
Insulin and sulfonylurea drugs lower blood sugar whether or not food has been eaten. On a fasting day the dose keeps working with no meal to meet it. A 2020 review of the fasting trials concluded that there is "an increased risk of hypoglycaemia" in people with type 2 diabetes "who are treated with insulin or sulphonylureas" (PMID 32372521). Signs of low blood sugar (hypoglycemia) are shakiness, sweating, a fast heartbeat and confusion, and at lower levels seizure or loss of consciousness.
What the trials report, and what their researchers did about medication:
- The 12-month 5:2 trial. Medications likely to cause low blood sugar were reduced at the start under a written protocol. In the first 2 weeks, low or high blood sugar events were similar in the two diet groups (a mean of 3.2 events with daily restriction and 4.9 with 5:2; P = .28) and affected 35% of the participants who used sulfonylureas, insulin or both (16 of 46) (PMID 30646030).
- A test of two medication protocols. An exploratory randomized study enrolled 42 adults with type 2 diabetes treated with sulfonylureas, insulin or both, tracked with flash glucose monitoring. Those who had low blood sugar during 2 weeks on their usual diet then followed the 5:2 pattern for 2 weeks. One protocol changed medication by HbA1c alone; the other also took account of low blood sugar events. The number of events changed by −1.0 under the fixed protocol and −3.5 under the adjusted one (P = 0.04), and over 60% of participants on the adjusted protocol had no events (PMID 30959146).
- Stopping drugs on fasting days. A 2016 discussion paper by the same group found 8 studies of very-low-calorie diets in type 2 diabetes that described medication changes; these usually required stopping medication to prevent low blood sugar. In the group's own 5:2 pilot, medication was stopped on the 2 fasting days only. The authors wrote that extensive blood glucose monitoring was still required to make individual reductions as weight fell (PMID 28031781).
- Insulin users. In the 12-week trial of three fasting days a week, with continuous glucose monitoring, no severe hypoglycemia occurred and the total daily insulin dose fell (PMID 36508320).
- The 2026 Personal View states that intermittent fasting "does not increase the risk of hypoglycaemia when medications are adjusted using simple rules"; its abstract does not give the rules (PMID 42361830).
In these trials the medication changes followed the researchers' protocols and blood sugar was monitored. None tested unmonitored fasting on unchanged doses of insulin or sulfonylureas. More on the condition: Hypoglycemia Awareness and Prevention.
Other Effects Reported
- In the 6-month trial in adults at risk of type 2 diabetes, adverse events were "transient and generally mild". Fatigue was reported more often with fasting than with daily calorie restriction or standard care; constipation and headache more often on both diets than with standard care (PMID 37024596).
- Food records from 38 overweight and obese people on the 5:2 pattern, with and without type 2 diabetes, showed a low fiber intake and intakes of calcium, zinc, magnesium and potassium below recommended guidelines; sodium intake exceeded the suggested daily target (PMID 32199696).
- In the network meta-analysis, time-restricted eating produced a small increase in total cholesterol and low-density lipoprotein cholesterol compared with whole-day fasting (PMID 40533200).
Type 1 Diabetes and Pregnancy
Type 1 diabetes is a state of absolute insulin deficiency. No fasting pattern, food or diet replaces insulin; without insulin, diabetic ketoacidosis develops, and it is fatal if untreated.
This page's sources contain no trial of intermittent fasting in type 1 diabetes. The 2026 Personal View found "insufficient data to recommend its use in people with type 1 or gestational diabetes" (PMID 42361830). The Ramadan guidance places people with type 1 diabetes and pregnant women with diabetes in its highest risk classes (PMID 36932771). The 2025 consensus statement describes insulin pump and sensor systems as showing promise for people with type 1 diabetes who fast; that is a statement about technology, not a trial result (PMID 40512040).
Limits of the Evidence
- Short and small. The type 2 diabetes trials on this page ran from 6 weeks to 12 months. The 2020 review describes the evidence as limited, "with small sample sizes and short trial durations", and long-term adherence as uncertain (PMID 32372521).
- Benefits faded with time. One trial's advantage over calorie restriction at month 6 was lost at month 18, and in the network meta-analysis the extra weight loss did not hold in trials of 24 weeks or longer.
- The pooled analyses disagree. They pooled different patterns, lengths and comparison diets.
- No blinding. A person knows whether they are fasting.
- Outcomes are blood tests and weight. None of the fasting trials described here reports on heart attacks, kidney disease, eye disease or deaths.
- Remission rests on one trial of 36 people per group with 12 months of follow-up.
- Not covered by any single trial among this page's sources: type 1 diabetes, pregnancy, and alternate-day fasting in people with diabetes.
Key Research Papers
- Pavlou V, Cienfuegos S, Lin S, Ezpeleta M, Ready K, Corapi S, et al.. Effect of Time-Restricted Eating on Weight Loss in Adults With Type 2 Diabetes: A Randomized Clinical Trial. JAMA Netw Open. 2023;6(10):e2339337. PubMed PMID: 37889487
- Carter S, Clifton PM, Keogh JB. Effect of Intermittent Compared With Continuous Energy Restricted Diet on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Noninferiority Trial. JAMA Netw Open. 2018;1(3):e180756. PubMed PMID: 30646030
- Guo L, Xi Y, Jin W, Yuan H, Qin G, Chen S, et al.. A 5:2 Intermittent Fasting Meal Replacement Diet and Glycemic Control for Adults With Diabetes: The EARLY Randomized Clinical Trial. JAMA Netw Open. 2024;7(6):e2416786. PubMed PMID: 38904963
- Obermayer A, Tripolt NJ, Pferschy PN, Kojzar H, Aziz F, Müller A, et al.. Efficacy and Safety of Intermittent Fasting in People With Insulin-Treated Type 2 Diabetes (INTERFAST-2)-A Randomized Controlled Trial. Diabetes Care. 2023;46(2):463-468. PubMed PMID: 36508320
- Yang X, Zhou J, Shao H, Huang B, Kang X, Wu R, et al.. Effect of an Intermittent Calorie-restricted Diet on Type 2 Diabetes Remission: A Randomized Controlled Trial. J Clin Endocrinol Metab. 2023;108(6):1415-1424. PubMed PMID: 36515429
- Kramer CK, Zinman B, Feig DS, Retnakaran R. Effect of Time-Restricted Eating on β-Cell Function in Adults With Type 2 Diabetes. J Clin Endocrinol Metab. 2025;110(6):e2045-e2053. PubMed PMID: 39193706
- Teong XT, Liu K, Vincent AD, Bensalem J, Liu B, Hattersley KJ, et al.. Intermittent fasting plus early time-restricted eating versus calorie restriction and standard care in adults at risk of type 2 diabetes: a randomized controlled trial. Nat Med. 2023;29(4):963-972. PubMed PMID: 37024596
- Sutton EF, Beyl R, Early KS, Cefalu WT, Ravussin E, Peterson CM. Early Time-Restricted Feeding Improves Insulin Sensitivity, Blood Pressure, and Oxidative Stress Even without Weight Loss in Men with Prediabetes. Cell Metab. 2018;27(6):1212-1221.e3. PubMed PMID: 29754952
- Tsitsou S, Bali T, Adamantou M, Saridaki A, Poulia KA, Karagiannakis DS, et al.. Effects of a 12-Week Mediterranean-Type Time-Restricted Feeding Protocol in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomised Controlled Trial-The 'CHRONO-NAFLD Project'. Aliment Pharmacol Ther. 2025;61(8):1290-1309. PubMed PMID: 40017349
- Semnani-Azad Z, Khan TA, Chiavaroli L, Chen V, Bhatt HA, Chen A, et al.. Intermittent fasting strategies and their effects on body weight and other cardiometabolic risk factors: systematic review and network meta-analysis of randomised clinical trials. BMJ. 2025;389:e082007. PubMed PMID: 40533200
- Khalafi M, Habibi Maleki A, Symonds ME, Rosenkranz SK, Rohani H, Ehsanifar M. The effects of intermittent fasting on body composition and cardiometabolic health in adults with prediabetes or type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab. 2024;26(9):3830-3841. PubMed PMID: 38956175
- Huang X, Huang G, Wei G. Intermittent fasting for glycemic control in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Nutr Hosp. 2025;42(2):356-365. PubMed PMID: 40008664
- Sharma SK, Mudgal SK, Kalra S, Gaur R, Thakur K, Agarwal R. Effect of Intermittent Fasting on Glycaemic Control in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials. touchREV Endocrinol. 2023;19(1):25-32. PubMed PMID: 37313231
- Rajpal A, Ismail-Beigi F. Intermittent fasting and 'metabolic switch': Effects on metabolic syndrome, prediabetes and type 2 diabetes. Diabetes Obes Metab. 2020;22(9):1496-1510. PubMed PMID: 32372521
- Varady KA, Chow LS, Peterson CM. Intermittent fasting to treat diabetes: time to update clinical practice guidelines. Lancet Diabetes Endocrinol. 2026;14(9):778-786. PubMed PMID: 42361830
- Carter S, Clifton PM, Keogh JP. Flash glucose monitoring for the safe use of a 2-day intermittent energy restriction in patients with type 2 diabetes at risk of hypoglycaemia: An exploratory study. Diabetes Res Clin Pract. 2019;151:138-145. PubMed PMID: 30959146
- Carter S, Clifton PM, Keogh JB. Intermittent energy restriction in type 2 diabetes: A short discussion of medication management. World J Diabetes. 2016;7(20):627-630. PubMed PMID: 28031781
- Scholtens EL, Krebs JD, Corley BT, Hall RM. Intermittent fasting 5:2 diet: What is the macronutrient and micronutrient intake and composition? Clin Nutr. 2020;39(11):3354-3360. PubMed PMID: 32199696
- Abdelrahim D, Faris ME, Hassanein M, Shakir AZ, Yusuf AM, Almeneessier AS, et al.. Impact of Ramadan Diurnal Intermittent Fasting on Hypoglycemic Events in Patients With Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials and Observational Studies. Front Endocrinol (Lausanne). 2021;12:624423. PubMed PMID: 33763029
- Ibrahim M, Ba-Essa EM, Ahmed A, Ahmad E, Annabi FA, Chaabane H, et al.. Recommendations for the Management of Diabetes During Ramadan Applying the Principles of the ADA/ EASD Consensus: Update 2025. Diabetes Metab Res Rev. 2025;41(5):e70057. PubMed PMID: 40512040
- Alam AY. Pre-Ramadan diabetes risk stratification and patient education. J Pak Med Assoc. 2023;73(3):374-376. PubMed PMID: 36932771
- V RA, Zargar AH. Diabetes control during Ramadan fasting. Cleve Clin J Med. 2017;84(5):352-356. PubMed PMID: 28530893
- Beshyah SA, Chowdhury TA, Ghouri N, Lakhdar AA. Risk of diabetic ketoacidosis during Ramadan fasting: A critical reappraisal. Diabetes Res Clin Pract. 2019;151:290-298. PubMed PMID: 30836132
PubMed Topic Searches
Connections
- Diabetes
- Natural Remedies for Blood Sugar
- Type 2 Diabetes
- Insulin Resistance
- Low-Carbohydrate Diet for Blood Sugar
- Exercise and Meal Timing for Blood Sugar
- Continuous Glucose Monitoring
- Reversing Insulin Resistance: Diet and Fasting Protocols
- Hypoglycemia Awareness and Prevention
- Hemoglobin A1C
- Fasting: Intermittent and Extended
- The Diabetes Code: Jason Fung on Type 2 Diabetes